0001641172-25-012695.txt : 20250528 0001641172-25-012695.hdr.sgml : 20250528 20250528161536 ACCESSION NUMBER: 0001641172-25-012695 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 EFFECTIVENESS DATE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-547407 FILM NUMBER: 25995591 BUSINESS ADDRESS: STREET 1: 505 MONTGOMERY STREET STREET 2: 10TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 505 MONTGOMERY STREET STREET 2: 10TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 D 1 primary_doc.xml X0708 D LIVE 0000109657 GT Biopharma, Inc. 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 800-304-9888 DELAWARE OXIS INTERNATIONAL INC. DDI PHARMACEUTICALS INC. DIAGNOSTIC DATA, INC. OXIS INTERNATIONAL INC DDI PHARMACEUTICALS INC DIAGNOSTIC DATA INC /DE/ Corporation true Michael Breen 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 Executive Officer Director Chief Executive Officer Alan Urban 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 Executive Officer Chief Financial Officer Charles Casamento 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 Director Hilary Kramer 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 Director Andrew Ritter 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA CALIFORNIA 94111 Director Biotechnology Decline to Disclose 06b false 2025-05-14 true true false 0 20000000 0 20000000 Offering is a committed equity facility under which the issuer has the right, in its sole discretion, to sell to the investor up to an aggregate of $20,000,000 of the issuer's common stock from time to time. false 2 0 0 0 false GT Biopharma, Inc. /s/ Alan Urban Alan Urban Chief Financial Officer 2025-05-28